Targeting the Resistance in Multiple Myeloma

Targeting the Resistance in Multiple Myeloma

Multiple myeloma is a hematological cancer characterized by the clonal proliferation of malignant plasma cells in the bone marrow. That disease has a rather low incidence but displays a high rate of relapse and resistance to conventional therapies. It is therefore necessary to find new therapeutic s...

Full description

Bibliographic Details
Main Authors:	Micaela Freitas, Mark E. Issa, Muriel Cuendet
Format:	Article
Language:	English
Published:	MDPI AG 2019-04-01
Series:	Proceedings
Subjects:	multiple myeloma 3D co-culture model cancer resistance
Online Access:	https://www.mdpi.com/2504-3900/11/1/3

Similar Items

Withanolide D Exhibits Similar Cytostatic Effect in Drug-Resistant and Drug-Sensitive Multiple Myeloma Cells
by: Mark E. Issa, et al.
Published: (2017-09-01)

Withanolide D Exhibits Similar Cytostatic Effect in Drug-Resistant and Drug-Sensitive Multiple Myeloma Cells
by: Issa, Mark E., et al.
Published: (2017)

Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma
by: Jennifer Sun, et al.
Published: (2020-01-01)

Chromothripsis in Treatment Resistance in Multiple Myeloma
by: Kyoung Joo Lee, et al.
Published: (2017-09-01)

Immunoglobulin D Multiple Myeloma Presenting as Spontaneous Fracture
by: Samer Al Hadidi, et al.
Published: (2017-03-01)

Hypoxia: Progressive Multiple Myeloma and Its Therapy Resistance
by: Ogechi Charity Obayi, et al.
Published: (2021-04-01)

Multiple Myeloma: Available Therapies and Causes of Drug Resistance
by: Vanessa Pinto, et al.
Published: (2020-02-01)

Rational Targeting of Cdc42 Overcomes Drug Resistance of Multiple Myeloma
by: Phuong Nguyen, et al.
Published: (2019-10-01)

STAT3: A Promising Therapeutic Target in Multiple Myeloma
by: Phyllis S. Y. Chong, et al.
Published: (2019-05-01)

Metabolic Effects of Recurrent Genetic Aberrations in Multiple Myeloma
by: Timon A. Bloedjes, et al.
Published: (2021-01-01)

Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma
by: Zhihong Zheng, et al.
Published: (2018-02-01)

THE EFFECT OF MULTIDRUG RESISTANCE GENE EXPRESSION ON THE CLINICAL COURSE OF MULTIPLE MYELOMA
by: Yu. B. Chernykh, et al.
Published: (2017-01-01)

Determination of intrarenal resistance index (RI) in patients with multiple myeloma
by: Schiemann U, et al.
Published: (2010-05-01)

Bortezomib resistance in multiple myeloma is associated with increased serine synthesis
by: Esther A. Zaal, et al.
Published: (2017-08-01)

Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma
by: Machin, Reinaldo Franqui
Published: (2018)

The Transfer of Sphingomyelinase Contributes to Drug Resistance in Multiple Myeloma
by: Sylvia Faict, et al.
Published: (2019-11-01)

Introduction to the special section on multiple myeloma
by: Chang, C.Y, et al.
Published: (2022)

Dihydroartemisinin Induces Growth Arrest and Overcomes Dexamethasone Resistance in Multiple Myeloma
by: Ying Chen, et al.
Published: (2020-05-01)

Promising Anti-Mitochondrial Agents for Overcoming Acquired Drug Resistance in Multiple Myeloma
by: Vanessa Innao, et al.
Published: (2021-02-01)

Chromosomal aberrations in multiple myeloma: A study on Indian population
by: Angel Beula P. Royal, et al.
Published: (2018-01-01)

Targeted Therapies for Multiple Myeloma
by: Christopher Chang-Yew Leow, et al.
Published: (2021-04-01)

Molecular genetic studies of Chinese multiple myeloma.
Published: (2005)

Effectiveness of bortezomib and bortezomib-containing programs FOR the treatment of recurrent and resistant multiple myeloma
by: T A Mitina, et al.
Published: (2010-07-01)

Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
by: Ilaria Saltarella, et al.
Published: (2020-01-01)

Corrigendum: Dihydroartemisinin Induces Growth Arrest and Overcomes Dexamethasone Resistance in Multiple Myeloma
by: Ying Chen, et al.
Published: (2021-07-01)

DNA methylation studies in multiple myeloma.
Published: (2004)

A cytogenetic and epigenetic study on multiple myeloma in Chinese.
Published: (2003)

Multiple Myeloma: An Update
by: Khalil Al-Farsi
Published: (2013-01-01)

EZH2 as a therapeutic target for multiple myeloma and other haematological malignancies
by: Rosemarie Tremblay-LeMay, et al.
Published: (2018-12-01)

Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors
by: Joel G. Turner, et al.
Published: (2016-08-01)

Tumour Dissemination in Multiple Myeloma Disease Progression and Relapse: A Potential Therapeutic Target in High-Risk Myeloma
by: Mara N. Zeissig, et al.
Published: (2020-12-01)

PIM Kinases in Multiple Myeloma
by: Jian Wu, et al.
Published: (2021-08-01)

Unusual Presentation of Multiple Myeloma
by: Sang Yeoup Lee, et al.
Published: (2018-02-01)

Bruton’s Tyrosine Kinase Targeting in Multiple Myeloma
by: Max Von Suskil, et al.
Published: (2021-05-01)

Liver Mass: An Unusual Presentation of Multiple Myeloma
by: Mhadgut, Hemendra, M.D., et al.
Published: (2020)

Targeting phosphoinositide 3-kinases and histone deacetylases in multiple myeloma
by: Seiichi Okabe, et al.
Published: (2021-03-01)

Challenges for Immunotherapy in Multiple Myeloma: Bone Marrow Microenvironment-Mediated Immune Suppression and Immune Resistance
by: Lisa C. Holthof, et al.
Published: (2020-04-01)

Bone Marrow Stromal Cells-Induced Drug Resistance in Multiple Myeloma
by: Roberto Ria, et al.
Published: (2020-01-01)

A Case of Multiple Myeloma Following Bladder Cancer
by: Hamid Shafi, et al.
Published: (2016-04-01)

Bioactive Compounds from Herbal Medicine Targeting Multiple Myeloma
by: Coralia Cotoraci, et al.
Published: (2021-05-01)